Denali Therapeutics Inc (NASDAQ:DNLI) does about 1.25M shares in volume on a normal day but saw 1039488 shares change hands in Tuesday’s trading. The company now has a market cap of 2.40B USD. Its current market price is $16.85, marking a decrease of -1.69% compared to the previous close of $17.14. The 52 week high reached by this stock is $33.31 whilst the lowest price level in 52 weeks is $14.56.
Denali Therapeutics Inc (DNLI) has a 20-day trading average at $16.68 and the current price is -49.41% off the 52-week high compared with 15.73% distance from its 52-week low. The 50-day simple moving average of the closing price is $18.88 and its 200-day simple moving average is $20.25. If we look at the stock’s price movements over the week, volatility stands at 5.79%, which decreases to 4.56% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 46.48 to suggest the stock is neutral.
The consensus objective for the share price is $40.27, suggesting that the stock has a potential upside of 58.16% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on December 13, 2023 when Citigroup initiated the stock to “Buy” and issued a price target of $32. Cantor Fitzgerald resumed its price target at $85-$35.
Denali Therapeutics Inc (DNLI) stock is up 9.13% over the week and -11.50% over the past month. Its price is -21.48% year-to-date and -36.46% over the past year.
To reach the target analysts have set, the stock logically needs to grow 58.16 percent from here.
The company has a return on investment of -13.50% and return on equity of -14.01%. The beta has a value of 1.34. Price to book ratio is 2.26 and price to sales ratio is 7.27.
